Anti-PD-1-iRGD Peptide Conjugate Boosts Antitumor Efficacy via Engagement Augmentation and Penetration Enhancement of T cells
Y. Pan, Q. Xue, Y. Yang, T. Shi, H. Wang, X. Song, Y. Luo, B. Liu, Z. Song, J. P. Li, J. Wei
This paper develops a PD-1-iRGD conjugate that enhances antitumor efficacy by improving T cell engagement and penetration, and expands a unique population of CD8+ T cells in the tumor microenvironment.
bioRxiv · Aug 4, 2023 · PreprintImmunology